SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19.

Peter ChenAjay NirulaBarry HellerRobert L GottliebJoseph BosciaJason MorrisGregory HuhnJose CardonaBharat MocherlaValentina StosorImad ShawaAndrew C AdamsJacob Van NaardenKenneth L CusterLei ShenMichael DuranteGerard OakleyAndrew E SchadeJanelle SaboDipak R PatelPaul KlekotkaDaniel M Skovronskynull null

Published in: The New England journal of medicine (2020)

In this interim analysis of a phase 2 trial, one of three doses of neutralizing antibody LY-CoV555 appeared to accelerate the natural decline in viral load over time, whereas the other doses had not by day 11. (Funded by Eli Lilly; BLAZE-1 ClinicalTrials.gov number, NCT04427501.).

Keyphrases

sars cov
respiratory syndrome coronavirus
dengue virus
coronavirus disease
zika virus